Literature DB >> 32053139

An Emerging Paradigm for Germline Testing in Pancreatic Ductal Adenocarcinoma and Immediate Implications for Clinical Practice: A Review.

Michael Rainone1,2, Isha Singh1,2, Erin E Salo-Mullen1, Zsofia K Stadler1,3, Eileen M O'Reilly1,3,4.   

Abstract

Importance: Pancreatic ductal adenocarcinoma (PDAC) is a malignant neoplasm with a rising incidence and is a leading public health challenge. Pancreatic ductal adenocarcinoma has been well characterized genomically, with findings of therapeutic actionability that have substantive implications for clinical practice based on recent high-level evidence. Observations: Pathogenic germline alterations (PGAs) are relatively common in individuals with PDAC, as evidenced in multiple recent data sets, with a frequency of approximately 10%. The most common PGAs are in BRCA1, BRCA2, and ATM and more rarely in PALB2, MLH1, MSH2, MSH6, PMS2, CDKN2A, and TP53, among others, with an aggregate frequency of 3.8% to 9.7%. These PGAs are of key interest owing to therapeutic actionability and the downstream identification of at-risk family members and possible hereditary cancer syndromes. Approximately 3% to 7% of individuals with PDAC harbor a BRCA1 or BRCA2 mutation, which are among the most frequently mutated genes in PDAC. Recent updates to the American Society of Clinical Oncology and the National Comprehensive Cancer Network guidelines recommend risk assessment for all individuals with PDAC irrespective of personal or family history or ethnicity. Treatment implications include the use of checkpoint inhibitor therapy for mismatch repair-deficient PDAC and the validation of poly-ADP (adenosine diphosphate)-ribose polymerase inhibitor (PARPi) therapy as a maintenance strategy in platinum-sensitive PDAC. Conclusions and Relevance: With increasing evidence and slow improvement of outcomes, PDAC has entered the era of precision medicine. Germline mutations have been identified in key genes with an aggregate frequency of 3.8% to 9.7%, several of which are therapeutically actionable with platinum, PARPi, and checkpoint inhibitor therapy. Potential therapeutic targets need to be actively sought and identified.

Entities:  

Year:  2020        PMID: 32053139     DOI: 10.1001/jamaoncol.2019.5963

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN: 2374-2437            Impact factor:   31.777


  10 in total

Review 1.  Pancreatic Cancer: A Review.

Authors:  Wungki Park; Akhil Chawla; Eileen M O'Reilly
Journal:  JAMA       Date:  2021-09-07       Impact factor: 157.335

2.  Concurrent Germline BRCA1/2 and Mismatch Repair Mutations in Young-Onset Pancreatic and Colorectal Cancer: The Importance of Comprehensive Germline and Somatic Characterization to Inform Therapeutic Options.

Authors:  Muhammet Ozer; Megha Ranganathan; Nicolas Lecomte; Juan M Schvartzman; Henry S Walch; Walid K Chatila; Jungeui Hong; Maria I Carlo; Michael F Walsh; Margaret Sheehan; Diana Mandelker; Ozge Ceyhan-Birsoy; Anna Maio; Yelena Kemel; Christine A Iacobuzio-Donahue; Eileen M O'Reilly; Kenneth H Yu
Journal:  JCO Precis Oncol       Date:  2022-06

3.  Pancreatic cancer risk to siblings of probands in bilineal cancer settings.

Authors:  Kari G Rabe; Maria A Stevens; Amanda Toledo Hernández; Shruti Chandra; Joleen M Hubbard; Jennifer L Kemppainen; Shounak Majumder; Gloria M Petersen
Journal:  Genet Med       Date:  2022-02-25       Impact factor: 8.864

4.  Pancreatic ductal adenocarcinoma in the era of precision medicine.

Authors:  Binbin Zheng-Lin; Eileen M O'Reilly
Journal:  Semin Oncol       Date:  2021-02-11       Impact factor: 4.929

Review 5.  Pancreatic Cancer Immuno-oncology in the Era of Precision Medicine.

Authors:  Samarth Hegde
Journal:  Indian J Surg Oncol       Date:  2020-08-25

Review 6.  Pancreatic adenocarcinoma: Beyond first line, where are we?

Authors:  Sara Cherri; Silvia Noventa; Alberto Zaniboni
Journal:  World J Gastroenterol       Date:  2021-05-07       Impact factor: 5.742

Review 7.  Multimodality therapy in metastatic pancreas cancer with a BRCA mutation and durable long-term outcome: biology, intervention, or both?

Authors:  Thomas L Sutton; Aaron Grossberg; Frederick Ey; Eileen M O'Reilly; Brett C Sheppard
Journal:  Cancer Biol Ther       Date:  2021-10-25       Impact factor: 4.742

8.  Targeting DNA Damage Repair Mechanisms in Pancreas Cancer.

Authors:  Lukas Perkhofer; Talia Golan; Pieter-Jan Cuyle; Tamara Matysiak-Budnik; Jean-Luc Van Laethem; Teresa Macarulla; Estelle Cauchin; Alexander Kleger; Alica K Beutel; Johann Gout; Albrecht Stenzinger; Eric Van Cutsem; Joaquim Bellmunt; Pascal Hammel; Eileen M O'Reilly; Thomas Seufferlein
Journal:  Cancers (Basel)       Date:  2021-08-24       Impact factor: 6.639

9.  Deciphering Genetic Alterations of Taiwanese Patients with Pancreatic Adenocarcinoma through Targeted Sequencing.

Authors:  Chi-Cheng Huang; Chih-Yi Liu; Chi-Jung Huang; Yao-Chun Hsu; Heng-Hui Lien; Jia-Uei Wong; Feng-Chuan Tai; Wen-Hui Ku; Chi-Feng Hung; Jaw-Town Lin; Ching-Shui Huang; Han-Sun Chiang
Journal:  Int J Mol Sci       Date:  2022-01-29       Impact factor: 5.923

10.  Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes.

Authors:  Parisa Momtaz; Catherine A O'Connor; Joanne F Chou; Marinela Capanu; Wungki Park; Chaitanya Bandlamudi; Michael F Berger; David P Kelsen; Sarah P Suehnholz; Debyani Chakravarty; Kenneth H Yu; Anna M Varghese; Alice Zervoudakis; Jia Li; Geoffrey Y Ku; Jennifer S Park; Marina Shcherba; James J Harding; Zoe Goldberg; Ghassan K Abou-Alfa; Erin E Salo-Mullen; Zsofia K Stadler; Christine A Iacobuzio-Donahue; Eileen M O'Reilly
Journal:  Cancer       Date:  2021-08-05       Impact factor: 6.921

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.